{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"56"},{"groupId":"BG006","value":"58"},{"groupId":"BG007","value":"148"}],"units":"Participants"}],"groups":[{"description":"Protocol therapy will consist of 20 mg MLN0128 (TAK-228) administered weekly on days 1, 8, 15, and 22 over a 28-day cycle.","id":"BG000","title":"Phase I - Dose Level 0"},{"description":"Protocol therapy will consist of 25 mg MLN0128 (TAK-228) administered weekly on days 1, 8, 15, and 22 over a 28-day cycle.","id":"BG001","title":"Phase I - Dose Level 1"},{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly on days 1, 8, 15, and 22 over a 28-day cycle.","id":"BG002","title":"Phase I - Dose Level 2"},{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"BG003","title":"Phase II - Analysis Group 1 MLN0128"},{"description":"Patients receive 800mg Pazopanib orally once daily over a 4-week cycle in the first intervention period/initial treatment period.","id":"BG004","title":"Phase II - Analysis Group 1 Pazopanib"},{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"BG005","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"BG006","title":"Phase II - Analysis Group 2 Pazopanib"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.7","value":"47.3"},{"groupId":"BG001","spread":"12.3","value":"56.3"},{"groupId":"BG002","spread":"16.0","value":"48.7"},{"groupId":"BG003","spread":"11.2","value":"53.2"},{"groupId":"BG004","spread":"16.0","value":"53.0"},{"groupId":"BG005","spread":"13.4","value":"59.7"},{"groupId":"BG006","spread":"13.6","value":"55.7"},{"groupId":"BG007","spread":"13.5","value":"56.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"40"},{"groupId":"BG006","value":"37"},{"groupId":"BG007","value":"96"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"21"},{"groupId":"BG007","value":"52"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"10"},{"groupId":"BG005","value":"44"},{"groupId":"BG006","value":"48"},{"groupId":"BG007","value":"120"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"13"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"35"},{"groupId":"BG006","value":"28"},{"groupId":"BG007","value":"84"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"30"},{"groupId":"BG007","value":"64"}],"title":"1"}]}],"description":"Eastern Cooperative Oncology Group PS Scale: 0)Fully active, able to carry on all pre-disease performance without restriction; 1)Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2)Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3)Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4)Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Registered Phase I patients and Randomized Phase II patients"}